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Background: HIV reverse transcriptase (RT) is a key
target of anti-AIDS therapies. Structural studies of HIV-1
RT, unliganded and complexed with different non-
nucleoside inhibitors (NNIs), have pointed to a common
mode of binding and inactivation through distortion of
the polymerase catalytic site by NNIs containing two
hinged rings. The mode of binding of the TIBO family of
inhibitors is of interest because these compounds do not
fit the two-hinged-ring model.
Results: The structure of HIV-1 RT complexed with
9-chloro-TIBO (R82913) has been determined at 2.6 A
resolution. As reported for the lower resolution analysis
of another TIBO compound, this inhibitor binds at the
same site as other NNIs, but our higher resolution study
reveals the Ci-TIBO is distorted from the conformation
seen in crystals of the inhibitor alone. This allows
CI-TIBO to mimic the binding of NNIs containing two
hinged rings. Inhibitor-protein interactions are again
predominantly hydrophobic and the protein conforma-
tion corresponds to that seen in complexes with other
tight-binding NNIs.
Conclusions: Although Cl-TIBO is chemically very dif-
ferent from other NNIs, it achieves remarkable spatial
equivalence and shape complementarity with other NNIs
on binding to RT. Comparison of the different RT-NNI
complexes suggests modifications to the TIBO group of
inhibitors which might enhance their binding and hence,
potentially, their therapeutic efficacy.
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Introduction
HIV reverse transcriptase (RT) catalyzes an essential step in
HIV replication, namely the conversion of the viral RNA
genome into proviral DNA before it is integrated into the
host genome. It is a multifunctional enzyme, having
RNA-directed DNA polymerase, DNA-directed DNA
polymerase and ribonuclease (RNase) H activities. Its cen-
tral role in the replication of the virus, together with the
apparent lack of endogenous RT activity in mammalian
cells, makes RT a prime target for anti-AIDS treatments
and all currently approved therapies target this enzyme.
The RT molecule is a heterodimer consisting of a 560
residue chain (called p66) and a second chain comprising
the initial 440 residues of p66 (called p51). Crystal struc-
tures of RT [1-8] reveal that the p66 subunit folds into
five domains named fingers, palm, thumb, connection
and RNase H [1] (a nomenclature we use throughout)
and that the p51 subunit comprises the first four domains
of p66. Whilst the equivalent domains from each subunit
have a broadly similar fold, especially the fingers and
thumb domains, their relative arrangement in the two
subunits is radically different [1,4]. Both subunits contain
the residues important for polymerase activity but only in
p66 do these form an active site.
Many inhibitors of HIV RT have been discovered, and
these tend to divide into two categories. One category,
to which all currently approved anti-AIDS drugs belong,
are nucleoside analogues (e.g. AZT, ddl and ddC) that
act as DNA chain terminators. The second category
includes the non-nucleoside analogue inhibitors (NNIs).
These are chemically highly diverse, but all possess the
common feature of high selectivity for HIV-1 RT rela-
tive to HIV-2 RT, apparently interacting with the
enzyme at a single site close to, but distinct from, the p66
polymerase active site. In turn, the NNIs can be subdi-
vided into groups of chemically similar structures named
after representatives of each group [9].
Co-crystallization of HIV-1 RT with the NNI nevirap-
ine [10] led to the first structure determination of the
enzyme at medium resolution [1] and analysis of that
crystal form allowed many of the basic features of the
interaction with this NNI to be determined [2].
Recently, we have obtained a different crystal form, also
in the presence of NNIs [11], capable of diffraction to
2.2 A resolution and this allowed us to describe structures
of RT complexed with four NNIs [4]. These NNIs
belong to three different groups: two nevirapine
analogues (nevirapine [10] and 1051U91 [12]),
ca-anilinophenylacetamide (-APA; R90385) [13] and
hydroxyethoxymethylphenylthiothymine (HEPT) [14].
These inhibitors were found to bind at equivalent sites
with a high degree of spatial overlap and, given their
chemical diversity, with surprising shape similarity.
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In order to understand the mechanism of action of these
NNIs it is necessary to make detailed comparisons
between the inhibited and the unliganded enzyme.
Information on the unliganded enzyme is available from
studies on further crystal forms [6]. However, crystal
packing forces can produce considerable distortions of
this highly flexible enzyme making it difficult to impute
significance to observed changes. We have been able to
make more direct comparisons, having determined the
structure of unliganded RT in two crystal forms for
which we have also determined enzyme-inhibitor com-
plex structures [5]. These structures demonstrated that
loss and rebinding of NNIs can occur without significant
domain rearrangement and clearly indicated a common
mechanism for NNI inhibition through NNI-induced
distortion of the polymerase active site. Our conclusions
for NNI action received independent support from a
study of the pre-steady state kinetics of polymerization
[15]. This showed that NNIs inhibit a stage of polymer-
ization subsequent to binding of the primer/template,
and suggested that the rate of primer/template binding
was enhanced in the presence of NNIs. Both sources of
evidence suggest that NNI binding does not lock the
domain structure in an inactive state, one of the possible
modes of NNI action originally suggested by Kohlstaedt
et al. [1] and termed 'molecular arthritis'.
At the time that the work described in this paper was ini-
tiated, all of the NNIs for which there were structural
data relating to interactions with HIV-1 RT could be
thought of as consisting essentially of two linked rings, in
which the linker itself could be a third ring [4]; Ana-
logues of tetrahydroimidazo-(4,5,1-1-jk)(1,4)-benzodi-
azepin-2(1H)-one (TIBO) [16] form a large group of
NNIs, some of which are very potent HIV-1 RT
inhibitors. These molecules (Fig. 1) cannot be fitted into
the 'two-hinged-ring' model. However, analysis of resis-
tance mutations and biochemical data suggest that they
bind in the same position as other NNIs.
In this paper we report the 2.6 A resolution crystal struc-
ture of HIV-1 RT complexed with 9-chloro-TIBO
(R82913 [16]), hereafter simply referred to as C1-TIBO.
The orientation and conformation of the drug and sur-
rounding protein are clearly defined allowing a detailed
description of the RT/Cl-TIBO interactions. In spite of
the different chemical structure of Cl-TIBO, the bound
inhibitor is arranged so as to preserve the key interactions
seen before and supports the proposal of a common
mechanism of inhibition by NNIs. Very recently, a lower
resolution analysis of a different TIBO analogue in com-
plex with RT was reported [8]. Although the global
positioning of the compound in the NNI-binding pocket
is similar, there are numerous and significant differences
in the conformations of both the enzyme and the
inhibitor when compared with our structure. We find
that the essential features of the drug-binding pocket are
unaffected by changes in pH, bound drug or crystal
packing ([4]; and our unpublished data) leading us to
believe that the differences in these analyses of TIBO
Fig. 1. The structure of 9-chloro-TIBO (R82913) showing the
numbering of atoms in the ring system and the required stereo-
specificity of the 5-methyl substituent.
complexes are due largely to minor errors in the lower
resolution analysis, rather than to slight differences
between the TIBO analogues or the different crystalliza-
tion conditions.
Results and discussion
Overall structure
The principal data set was collected from a single crystal
of the RT/C1-TIBO complex flash-cooled to 105 K at
the Synchrotron Radiation Source (SRS), Daresbury
Laboratory, UK. Data collection, reduction and refine-
ment details are given in Table 1. The final model had an
R-factor of 22.4% for all data from 25-2.6 A resolution,
with good stereochemistry and 88% of the residues
adopting conformations in the most favoured region of
the Ramachandran plot [17].
Our crystals of RT demonstrate very variable unit cell
dimensions as a result of domain movements within the
RT heterodimer on dehydration of the crystal. Previ-
ously, we have observed five characteristic orthorhombic
cells, denoted forms A-E [5,11]. The RT/Cl-TIBO
complex crystal was of a sixth (F) form with unit cell
dimensions a=138.8 A, b=115.8 A and c=66.2 A. The
domain arrangement in the RT heterodimer is very simi-
lar to that observed in form D [4] (see below), but with
an even lower solvent content (46% versus 48%). This
crystal form has the smallest cell volume of any observed
so far, with dehydration and cooling reducing the
amount of solvent in the unit cell by 33% relative to form
A, in which the crystals originally grow.
Comparison between form D and form F models reveals
no major structural changes. A rotation of 0.7 superposes
the Cot traces for the two structures with a root mean
square (rms) deviation of 0.5 A. Superpositions of.
Cl
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individual domains show that the largest change in the
relative orientation of the domains is a 1.50 rotation of the
p66 palm. The similarity to the form D RT-nevirapine
complex model [4] provides an ideal reference point for
describing the structure. The secondary-structure assign-
ment for the RT/Cl-TIBO complex agrees well with our
other models [4] and therefore we use this nomenclature
throughout. Significant structural changes from the
RT-nevirapine complex are confined largely to the NNI.
Metal ion binding in the RNase H domain
Although the structure is not significantly rearranged in
regions distant from the NNI site compared with our
other RT-inhibitor complexes [4], the reduction in cell
size does have some effect on the definition of parts of the
structure. In particular, this cell form shows clearer elec-
tron density around proposed metal ion binding site(s) in
the RNase H domain (Fig. 2). Comparisons with struc-
tures for the isolated RNase H domain [18] and an unli-
ganded RT structure [6] suggest that the density
corresponds to a bound metal ion and part of a C-termi-
nal helix, ao16 (residues 543-552 as defined in [18]). From
our electron density, this helix appears to have rotated
slightly and moved away from 17 (residues 439-447)
Fig. 2. Omit I Fob I -I Fcalc I (red, contoured at 2) and
2 'Fobs -I Fcalc I (pale blue, contoured at 0.75(r) electron density
for the RNase H metal-binding site. The phasing model was the
nine-domain rigid-body refined model, shown by lines connect-
ing protein atoms. The position of the bound metal ion is shown
by a red sphere. The density corresponding to the final C-termi-
nal residue included in our model (His539) is marked by the let-
ter 'C'. The arrow lies along the density corresponding to the
helix a16 (residues 543-552).
relative to the other models. Good evidence exists for
a metal ion interacting with Asp443, Asp498 and
(probably) Asp549 in the gap between 1317 and a16.
Modelling this density as a water molecule results in it
having a very low B-factor (32 A2) compared with the
mean B-factor of the Asp443 and Asp498 carboxylate
groups (71 A2). It is not possible to identify the metal ion,
but, modelled as a full-occupancy magnesium ion, its
B-factor is 48 A2. Electron density for our other cell forms
(data not shown) revealed some occupancy of this putative
metal site, but did not allow us to. distinguish between a
water molecule and a low-occupancy metal ion.
This metal site is somewhat different from that observed
in the unliganded RT structure of Rodgers et al. [6] in
which rearrangement of the side chains creates a single
site between Asp443, Glu478 and Asp498, some 7 A from
our metal site. Davies et al. [18] observe two sites in their
structure of the isolated RNase H domain, with a third
arrangement of the key residues. One site approximates to
the site described by Rodgers et al., but only involves
Glu478 and Asp498. The other site involves Asp443 and
Asp549 and is about 4 A from our observed site. The evi-
dence from these structures is that the RNase H domain
Table 1. Statistics for crystallographic structure determination.
Data set Principal Partial
Data collection details
Data collection site SRS (1995) ESRF (1995)
Wavelength (A) 0.87 0.995
Collimation (mm) 0.18 0.10
Crystal form F E
No. of crystals 1 1
Unit cell (A) 138.8, 115.8, 136.6, 109.2,
66.2 70.8
Resolution range (A) 25.0-2.6 30.0-2.8
No. of observations 85 252 16 682
No. of unique reflections 27108 11 667
Completeness (%) 80.7 43.6
Reflections with F/(F)>3 21 290 9091
Rmerge (%)* 12.4 6.6
Outer resolution shell
Resolution range (A) 2.7-2.6 2.9-2.8
No. of unique reflections 2439 766
Completeness (%) 68.7 29.1
Reflections with F/(F)>3 1089 336
Refinement statistics
Resolution range (A) 25.0-2.6 8.0-3.0#
No. of unique reflections 27108 9697
R-factor t 0.224 0.375
No. of protein atoms 7712 7712
No. of water molecules 114
Rms bond length deviation (A) 0.007
Rms bond angle deviation () 1.4
Mean B-factor (A2)* 59/64/52/32
Rms backbone AB (A2)§ 3.6
*Rf = I -<i> I <I>. tR-factor= I Fobs-Fcac I/YFobs. *Mean
B-acTor for main-chain, side-chain, water and inhibitor atoms,
respectively. Rms deviation between B-factors for bonded
main-chain atoms. #Rigid-body refinement only, see text.
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can bind metal ions in a variety of ways, perhaps explain-
ing the apparently contradictory reports of metal ion
binding in other RNase H structures [19,20]. It is unclear
what the functional role of such versatility might be.
Inhibitor-binding pocket in the RT/CI-TIBO complex
The electron-density map allows the C1-TIBO to be
orientated unambiguously (Fig. 3a). The inhibitor binds
at the same site observed for other RT-NNI complexes
[1,2,4,7,8], some 10 A from the conserved, catalytically
important aspartic acid residues Asp1lO, Asp185 and
Asp186. The inhibitor makes predominantly hydro-
phobic contacts in a pocket with few electrostatic
features, in particular involving leucine, valine and tyro-
sine residues (Fig. 3b). Table 2 lists the surface area for
each residue shielded by the NNI. The only direct polar
interaction is a hydrogen bond between the nitrogen
atom of the imidazolone ring of C1-TIBO and the car-
bonyl oxygen of Lys101. The pocket has a volume of
700 A3, of which 250 A3 are occupied by the inhibitor
and additional volume is filled by two water molecules
(Fig. 3c). The pocket is connected with the bulk solvent
by a small channel between residues LyslOl, Va1179
(both from the p66 subunit) and Glu138 (from the p51
subunit), which is too narrow to allow passage of the
NNI in the static structure.
Conformation of bound CI-TIBO
The electron density (Fig. 3a) clearly shows the methyl
and dimethylallyl groups lying to either side of the almost
coplanar three-ring system which forms the core of
TIBO compounds. The conformation of bound
C1-TIBO in RT is different from conformations
observed in small-molecule crystals of this compound
[21], which contained two molecules in the asymmetric
unit (A and B), with distinct conformations. In form A,
the 5-methyl group is equatorial to the diazepin ring,
whereas in form B it has bent down bringing the
dimethylallyl group to the other side of the ring system.
On binding to RT this change proceeds further, leaving
the 5-methyl group in an axial position and the nitrogen
Fig. 3. The binding of CI-TIBO by RT. (a) Omit I Fobs -IFca c
electron density for the CI-TIBO molecule contoured at 3a. Map
produced by omitting the inhibitor from the phasing model after
refinement. CI-TIBO is shown in ball-and-stick representation,
water molecules are shown by red spheres and the surrounding
protein atoms are joined by lines. Atoms are coloured according
to type. (b) Schematic drawing showing the interactions between
CI-TIBO (red) and RT. Residues in close proximity (3.6 A) to any
of the NNIs we have studied are shown, those in close proximity
to CI-TIBO are highlighted in green. Distances from CI-TIBO are
indicated by broken lines (3.3 A in pink 3.3-3.6 A in light blue
and hydrogen bonds giving distances in A in black). The position
of a bound water molecule is indicated by a pink sphere. (c) The
binding pocket for CI-TIBO (delineated by the red surface) and the
bulk solvent (delineated by the blue surface). CI-TIBO is shown in
an atom-coloured ball-and-stick representation, water molecules
by small red spheres and the surrounding protein atoms are joined
by lines. The pocket surface represents the volume accessible to a
small probe (radius 1.4 A) but inaccessible to a probe of 2.5 A
radius, which is just unable to penetrate the pocket's narrow
entrance channel. (The pocket and solvent surfaces were calcu-
lated using VOLUMES [RE, unpublished program].)
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at position six with an inverted conformation (Fig. 4a).
This arrangement appears to be necessary for tight bind-
ing to RT. We have described a simple model for the
binding of nevirapine, 1051U91, ot-APA and HEPT by
RT by considering these NNIs as comprising two hinged
six-membered rings lying in very similar orientations [4].
HEPT was a partial exception to this model, but it was
also by far the weakest inhibitor studied. Cl-TIBO does
not fit this two-hinged-ring model because its fused ring
system does not have an intervening 'hinge' (Fig. 1), yet
it is a very potent inhibitor. The relative positions and
orientations (after superposition based solely on the
structure of the surrounding protein) of the inhibitors in
our five RT complexes are shown in Figure 4b. The
phenyl and imidazolone rings of C-TIBO occupy the
space of one of the rings in our two-hinged-ring model,
whilst the planar hydrophobic dimethylallyl substituent
folds so as to mimic the other ring. Thus, despite chemi-
cal differences, the bound conformation of C-TIBO is
very similar in shape to the bound conformations of
other NNIs.
The bound conformation of Cl-TIBO has additional
shape similarities to other NNIs resulting from its sub-
stituents. In particular, the 5-methyl group on the
diazepin ring has spatially equivalent groups in the other
NNIs, namely, cyclopropyl in nevirapine, ethyl in
1051U91, amide in -APA and methyl in HEPT. Such
spatial equivalence can only be achieved by the
(+)-(S)-CH 3 enantiomer of Cl-TIBO, clearly explaining
the observed stereospecificity requirement [16]. The
9-chloro substituent partially occupies the volume filled
by the hydroxyethoxy group of HEPT. The shape and
size of this particular portion of the NNI-binding pocket
is variable, the surrounding protein structure appearing
to be quite 'plastic' [4]. Hence, there appears to be con-
siderable scope for variation in substituents occupying
this region of the binding pocket (in line with struc-
ture/activity relationship studies [16]).
Comparison with other modelled and experimental structures
Conformational variability in C-TIBO (Fig. 4a) has
undoubtedly contributed to the difficulties in predicting
the mode of interaction with HIV-1 RT (R Gussio et al.,
Abstract Medi 34, 208th ACS National Meeting, Wash-
ington DC, August, 1994; [22]), and indeed even in
interpreting a lower resolution crystallographic analysis of
RT complexed with a different TIBO analogue [8]. The
first modelling study attempted to predict the relative
bound orientations of Cl-TIBO and nevirapine on the
basis of their chemical similarity [23]. As both the nevi-
rapine and C-TIBO conformations used were obtained
from crystallographic analysis of the isolated inhibitors
[21,23], which differ from those observed in complex
with RT, it is not surprising that the proposed alignment
was radically different to that derived from our crystallo-
graphic analyses. In particular, the form A structure of
C1-TIBO [21] was used as it was considered to be slightly
favoured energetically. Thus, the modelled superposition
on nevirapine has the ring system of C-TIBO oppositely
orientated, with the chlorine and sulphur positions
roughly interchanged, compared with the observed rela-
tive orientation in our RT-NNI structures. A second
modelling study (N Pattabiraman et al., Abstract Medi
Table 2. Surface areas of each residue shielded by the non-nucleoside inhibitor (NNI), the nature of the interactions between each
residue and the NNI and the distribution of observed resistance mutations.
Residue NNI complexed to RT Mutation
nevirapine 1051 U91 ax-APA HEPT CI-TIBO
Pro95 4 (-) 2 (S) 6 (-) 5 (-) 6 (S)
Leu100 45 (S) 43 (MS) 57 (S) 34 (S) 49 (MS) lie
Lys101 4 (M) 6(-) 7 (M) 10 (M) 13 (MS) Glu
Lys103 9 (-) 13 (-) 17 (S) 12 (S) 9 (S) Asn, Gin
Val106 25 (S) 26 (S) 18 (S) 40 (S) 24 (S) Ala
Val 79 16 (MS) 19(S) 24 (MS) 5 (S) 29 (MS) Asp, Glu
Tyrl81 26 (S) 26 (S) 34 (S) 21 (-) 27 (S) Cys, lie, Phe
Tyrl 88 21 (MS) 22 (S) 24 (MS) 29 (S) 26 (MS) Cys, His, Leu
Glyl 90 4 (M) 5 (-) 3 (M) 4 (-) 2 (M) Ala, Glu
Pro225 - (-) - (-) - (-) 7 (S) - (-)
Phe227 4 (S) 7 (S) 5 (S) 10 (S) 7 (S)
Trp229 8 (S) 12 (-) 11 (S) 18 (S) 10 (S)
Leu234 17 (S) 16 (S) 16 (S) 15 (MS) 13 (MS)
His235 5 (M) 2 (M) 4 (M) 4 (M) 7 (M)
Pro236 2 (M) 5 (M) 2 (-) 15 (M) 3 (M) Leu
Tyr318 5 (S) 6 (S) 7 (S) 12 (S) 5 (S)
Glu138 (p51) 2 (-) 9 (S) 7 (S) -(-) 4 (-) Lys
Total 197 (MS) 219 (MS) 242 (MS) 241 (MS) 234 (MS)
Areas (in A2) show the change in accessible area for each residue as calculated in the presence and absence of each NNI in the
relevant RT-NNI model. The letters in parentheses indicate whether interactions between the residue and the NNI involve main-
chain atoms (M), side-chain atoms (S) or both sorts of atoms (MS). Residues which are shielded by the NNI but which are not in
direct contact (>4 A) are shown as (-). The final column indicates observed resistance mutations to any NNI 27], with those
reported against CI-TIBO (R82913) in bold type.
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Fig. 4. Comparison with other RT-NNI
complex structures. (a) Stereoview of the
conformation of bound CI-TIBO (red)
compared with the conformations
observed in the small-molecule struc-
tures [211. The form A conformation is
shown in pale blue and the form B con-
formation in darker blue. The structures
were superposed based on the atoms
comprising the two fused planar rings.
The change in the position of the
dimethylallyl side chain is marked I, the
5-methyl group is marked II with the
change in position indicated by an
arrow. (b) The positions, orientations
and conformations adopted by the NNIs
in the five RT-NNI complexes studied.
Two orthogonal views of the NNIs alone
are shown in ball-and-stick representa-
tion. (c) Stereoview of the NNI-binding
site in the RT/CI-TIBO complex. The
protein is shown in blue with relevant
secondary structure components
labelled. The catalytic aspartic acid
residues, the methionine (Met184)
residue with an unusual main-chain
conformation and the glutamine
(Gln182) residue which stabilizes it are
also labelled. CI-TIBO is shown by
yellow ball-and-stick representation. The
orange ball-and-stick shows the position
and orientation of nevirapine in the
equivalent RT complex. (d) Stereoview
of the superposition of the NNI-binding
sites for the RT/CI-TIBO (yellow) and
RT-nevirapine complexes (orange). The
NNIs are shown as ball-and-stick mod-
els, the backbone atoms of the protein
and side-chain atoms for those residues
within 3.6 A of the NNIs are shown con-
nected by thin lines. Reported resistance
mutations to CI-TIBO (R82913) [27] are
shown by colouring the appropriate side
chain in the RT/CI-TIBO model with
light blue stripes. The superposition pro-
cedure for generating parts (b-d) is
detailed in Table 3.
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33, and R Gussio et al., Abstract Medi 34, 208th ACS
National Meeting, Washington DC, August, 1994) with
Protein Data Bank (PDB) [24] entry code 1RVQ, is
based on the RT-nevirapine complex structure of
Kohlstaedt et al. [1] (PDB entry code HVT). In spite of
the correct nevirapine conformation being available, and
a model for the surrounding protein pocket, the confor-
mation is again incorrect. Based on the Liaw et al. [21]
form A conformation, the position of the dimethylallyl
group is approximately correct, but the phenyl and imi-
dazolone rings are rotated by 1600 from the orientation
that we observe. The resulting position for the 5-methyl
group is more akin to that of 8-position substituents.
Since our analysis was completed, a lower resolution
crystallographic analysis of RT complexed with
8-chloro-TIBO (R86183) has been reported [8]. The
overall orientation for both CI-TIBOs is the same, but
the quality of the data and state of refinement (in [8] the
crystallographic R-factor is 24.9% for reflections from
10-3.0 A resolution with Fobs> 2ar(Fobs), whereas in this
present study the equivalent R-factor is 18.6% for our
data and model) result in important differences between
the models which cannot be ascribed to the chemical dif-
ference between the inhibitors. In particular, the
8-Cl-TIBO has been modelled similarly to the Liaw et al.
[21] form B conformation, and this leads to a substantial
misplacement of the 5-methyl group (Fig. 4a) such that it
no longer occupies the volume described above, a con-
formational difference to which we attach significance.
We also consider the reported changes in the protein
conformation [8] between different RT-NNI complexes
to be largely artifactual because the similarity of the pro-
tein conformation in the binding site and the induced
shape complementarity of the inhibitors are particular
features of all of the RT-NNI complexes that we have
studied [4] (with the partial exception of RT-HEPT).
A theoretical study based on 'modified neglect of differ-
ential overlap' (MNDO) methods [22] recognized the
inherent flexibility of TIBO and suggested that the active
conformation could not be determined from such studies
alone. In spite of this, the superposition of TIBO on
nevirapine performed by these authors [22] was broadly
correct. It is interesting that this theoretical study, based
on the least experimental evidence, was in fact the most
perceptive in recognizing the possibility for inversion of
the 6-nitrogen conformation.
Comparison of NNI-binding sites in different RT-NNI
complexes
The similarity of the Cl-TIBO binding site to that in
other NNI complexes is exemplified by the comparison
with nevirapine in Figure 4c. The volume occupied by
CI-TIBO is 250 A3 , and of this volume 100 A3 is com-
mon to all five NNIs we have studied [4]. The total vol-
ume occupied by all five NNIs, after superposition based
on the binding site, is 440 A3. Although each inhibitor
makes some polar interactions with the protein, no such
interactions have equivalents in all complexes and no
bound water sites in the NNI pocket are common to all
of the complexes. However, the main-chain conforma-
tion of the protein is almost unaffected by the nature of
the NNI in the pocket. The changes in Ca positions rel-
ative to the RT-nevirapine complex for residues contact-
ing the NNI (Table 3) show that their positions in the
RT/Cl-TIBO complex are as similar to those of the
nevirapine complex as are the C positions of the
1051U91 complex, despite the far greater chemical simi-
larity between nevirapine and 1051U91 [4]. The side-
chain conformations adopted by the residues lining the
NNI pocket in the RT/Cl-TIBO complex are also very
similar to those for other tight-binding RT-NNI com-
plexes [4]. They are compared with the RT-nevirapine
structure in Figure 4d. For other complexes, the confor-
mations of the side chains of the three-stranded sheet
(,4, 7 and 8) containing the catalytic aspartic acid
residues have been observed to be like those in the
equivalent structure in the inactive p51 subunit [5]. This
also applies in the case of the Cl-TIBO complex, for
which the rms deviation between the p66 and p51 sub-
units for all atoms comprising 4, 7 and 8 is 1.0 A
(compared with 0.7-0.9 A in the other tight-binding
Table 3. Differences in Ca atom positions (in A) around the
NNI site for the RT-NNI models.
Residue Inhibitor
1051U91 a-APA HEPT CI-TIBO
Pro95 0.7 (38) 0.7 (29) 0.7 (48) 0.2 (46)
Leu100 0.3 (29) 0.2 (22) 0.7 (22) 0.6 (35)
Lysll01 0.4 (40) 0.2 (32) 0.5 (35) 0.5 (54)
Lys103 0.3 (38) 0.4 (37) 0.3 (43) 0.4 (59)
Val106 0.3 (25) 0.7 (30) 0.4 (29) 0.6 (60)
Val 179 0.3 (43) 0.3 (27) 0.7 (41) 0.6 (39)
Tyrl81 0.5 (28) 0.1 (26) 0.5 (43) 0.4 (44)
Tyrl83 0.5 (46) 0.2 (32) 0.6 (57) 0.5 (53)
Tyr188 0.6 (28) 0.2 (30) 0.5 (39) 0.7 (59)
Val189 0.4 (28) 0.3 (22) 0.3 (36) 0.5 (45)
Glyl90 0.3 (18) 0.4 (24) 0.1 (38) 0.5 (45)
Pro225 0.4 (60) 0.3 (59) 0.4 (80) 0.2 (65)
Phe227 0.7 (56) 0.4 (43) 0.4 (73) 0.7 (60)
Trp229 0.9 (70) 0.1 (41) 0.2 (63) 0.3 (56)
Leu234 0.3 (52) 0.1 (33) 0.6 (60) 0.2 (66)
His235 0.3 (59) 0.1 (39) 1.8 (64) 0.2 (67)
Pro236 0.3 (43) 0.2 (36) 2.7 (66) 0.6 (57)
Tyr318 0.5 (31) 0.1 (27) 0.7 (32) 0.1 (38)
Glu138 (p51) 0.4 (62) 1.5 (41) 0.8 (48) 0.2 (44)
The Ca positions for other RT-NNI models are compared with
the RT-nevirapine model, listing residues with at least one
atom within 4.0 A of the NNI. The temperature factor (in A2)
for each Ca atom (in parentheses) indicates its flexibility.
Models were first superposed to compensate for the different
crystal forms and domain rearrangements based on the 'core'
of the palm domain (residues 94-118, 156-215 and
225-243), residues 317-319 from the connection domain of
p66 and residues 137-139 from the fingers domain of p51.
The superpositions were performed using the program SHP
[36] with which 102 Cas from RT-1051U91, 109 Cas from
RT/a-APA, 96 Cas from RT-HEPT and 109 Cas from RT/CI-
TIBO were superposed onto the RT-nevirapine model with
rms deviations of 0.5 A, 0.4 A, 0.5 A and 0.5 A, respectively.
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NNI complexes, 1.5 A for the RT-HEPT complex and
2.1 A for the unliganded structure).
Comparison with unliganded RT structures
We have determined crystal structures for unliganded RT
in two of our unit cell forms (C and E) [5]. Unfortu-
nately, the model for the RT/Cl-TIBO complex is in a
different cell form from either of these, leading to rather
different domain orientations. This is not a result of the
binding of C1-TIBO as we have also obtained a partial
data set for the same complex in a different cell form
(form E; see the Materials and methods section). Refin-
ing the C1-TIBO structure, as rigid domains, against this
partial data set provides us with a second C1-TIBO
structure which then allows direct comparison with the
unliganded RT (Fig. 5). Aside from artifacts of the rigid-
body superposition at domain boundaries, significant
changes are almost entirely localized to the vicinity of the
Cl-TIBO-binding pocket. In particular, there is an
almost rigid-body shift in the 134, 137 and 38 sheet to
accommodate C1-TIBO. This supports our earlier obser-
vation that the concerted but subtle shift of 134, 37 and
38 on NNI binding and the resulting repositioning of
the catalytic aspartic acid residues within the polymerase
active site as a whole causes the inhibitory effect of these
compounds [5]. Since our results were submitted for
publication, another unliganded RT structure has been
reported [6] showing a large difference in orientation of
the thumb domain relative to other RT structures and it
has been suggested [6,8] that this, much larger, change is
mechanistically significant. We believe that the extra
flexibility observed for the thumb is entirely consistent
with our model. To be precise, we do not feel that the
observation by Rodgers et al. [6] of a domain configura-
tion incompatible with activity (the thumb domain is
observed closing off the active site) provides, in itself, an
explanation for the inhibitory properties of NNIs.
Instead, our structural data [5], and other kinetic
evidence [15] suggest that relatively subtle changes in the
positions of the catalytic aspartate residues account for
the inhibition of activity, with the concomitant increase
in rigidity of the thumb domain being responsible for the
increased substrate affinity of the inhibited enzyme.
Occurrence of Cl-TIBO resistance mutations
The use of NNIs for anti-AIDS monotherapy has been
largely ruled out because of the rapid selection of resistant
virus strains. Most mutations map to residues lining the
NNI-binding pocket, and thus are in direct contact with
the NNIs. A second class of mutations are those observed
for residues located near to the entrance to the pocket,
possibly affecting entry of the inhibitor. A small number
of key resistance mutations are found to be common to
many different tight-binding NNIs, including C1-TIBO.
The distribution of Cl-TIBO-resistance mutations is
summarized in Figure 4d and Table 2. Mutations at posi-
tions 100, 106, 181 and 188 are also observed with other
NNIs and are readily explained as these residues make
extensive side-chain contacts with C1-TIBO. However,
Fig. 5. Ribbon diagram of the form E RT/CI-TIBO complex using
colour coding to illustrate the structural variation from the unli-
ganded form E RT structure. CI-TIBO is shown as a space-filling
model. The form E RT/CI-TIBO model was produced by a nine-
domain rigid-body refinement of the form F model on to the par-
tial data set of form E. Hence, some artifactual variation can be
detected near the domain boundaries (light blue).
only two of the three NNI-induced mutations observed
for Tyr188 (Tyrl88--His and Tyrl88-Leu but not
Tyrl88-Cys) are found for Cl-TIBO. This may be
because Tyrl88 contacts the smaller dimethylallyl group
of C1-TIBO rather than a six-membered ring as it does
in the other complexes studied [1,2,4,7], thereby reduc-
ing the effectiveness of substitutions at this site in attenu-
ating binding. Mutations at positions 103 and 138 belong
to the second class as both substitutions involve changes
of charge, both residues are located near the entrance to
the pocket, and neither residue makes extensive contacts
with CI-TIBO.
Factors affecting the binding of Cl-TIBO by RT
RT-NNI complexes are primarily stabilized by extensive
hydrophobic interactions rather than specific polar ones.
The NNI pocket does not exist in the unliganded RT
structure [5,6]. It only forms upon insertion of the drug
between two hydrophobic faces previously in contact,
which causes a movement of the polypeptide backbone
and rearrangements of side chains. The 'drug-bound
conformation' of the three strands 34, [37 and 138 is very
similar to that of the equivalent sequence in the p51
chain [5], where these strands pack tightly against a
hydrophobic protein surface largely comprising ao10 and
the chain around Leu100. This provides a model for an
'ideal' NNI - it should mimic the contours appropriate
for each surface with which it comes into contact. Hence
NNIs tend to be fairly flat and apolar, filling a hole
formed as hydrophobic side chains snap from one con-
formation (p66 unliganded) to another (p51-like) and the
main chain rearranges slightly. It is therefore unsurprising
that the shapes of the bound NNIs are similar and that
they occupy a very similar place in the RT heterodimer
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[1,2,4,7]. However, the groups of compounds differ con-
siderably in detail and it is instructive to examine how
each fills the space of the pocket. Figure 6a shows the
total volume occupied by any of the five NNIs we have
studied, and the volume common to all of the inhibitors
is shown as a purple surface in Figures 6b,c. Now that we
have a reasonable database of structural information, this
common volume will give a fair indication of the volume
that any effective NNI must occupy, and hence provide a
model for predicting the position and conformation of
other NNIs in the pocket.
If we analyze the common volume in terms of our two-
ring model we find that the volume of one ring (the
lower ring in Fig. 6b,c) is almost perfectly occupied. The
other ring has some conserved volume, the dimethylallyl
group of Cl-TIBO overlapping with part of the (appar-
ently less than ideally oriented) HEPT ring. The rest of
the second hinged-ring volume is only occupied by
nevirapine, 1051U91 and 0(-APA.
A key volume is that occupied by the 5-methyl group in
C1-TIBO which is filled by a variety of chemical groups
Fig. 6. Volumes occupied by the bound
NNIs. (a) Stereoview of the surface
delineating the volume occupied by the
five NNIs in their respective RT com-
plexes. The surfaces were calculated by
superposing the RT models in the man-
ner described in Table 3. The surface is
coloured according to which inhibitor
contributes each part of the surface:
orange, nevirapine; red, 1051 U91; yel-
low, CI-TIBO; green, a-APA; purple,
HEPT. (b),(c) Orthogonal stereoviews of
the volume common to all five NNIs in
their respective RT complexes. (The
superposition is described in Table 3.)
The inhibitors are shown as ball-and-
stick models in the same colouring
scheme as part (a) and the common vol-
ume is delineated by the purple surface.
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in the other four NNIs [4]. It may be possible to substi-
tute a larger group here. Consideration of the other
NNIs suggests that it might be possible to accommodate
an ethyl group (Fig. 7). The need to fill this particular
volume may be the cause of the different conformation
of C1-TIBO compared with forms A and B of Liaw et al.
[21] as neither the form A nor the form B Cl-TIBO has
the 5-methyl group suitably oriented. Volume considera-
tions suggest variation at the 6-position may result in
molecules binding with different conformations for this
group. This may be the case with the diethylallyl sub-
stituent (R86162 [25]). Figure 6 suggests that possible
candidates for the 6-position could involve further substi-
tution of the double bond [e.g. -CH2 -C(Me)=C(Me) 2
or -CH2-C(Et)=C(Me) 2] or possibly a phenyl ring.
As well as showing the total volume occupied by any of
the NNIs we have studied, Figure 6a reveals volumes in
the pocket that are used by other NNIs but not by
C1-TIBO. One example of unused volume is that occu-
pied by the hydroxyethoxy chain of HEPT - this volume
is not fully exploited by the other four drugs, although the
9-chloro group of C1-TIBO occupies it partially. Whilst
HEPT itself is a rather weak inhibitor, close analogues are
much more potent, suggesting that this volume could be
used. Inspection of Figure 6c shows that 8-position sub-
stituents would be favourable as these correspond spatially
to one of the chlorine atoms in ot-APA [4,7] and to the
Fig. 7. An atom-coloured ball-and-stick diagram of CI-TIBO show-
ing the features of the molecule responsible for its tight binding to
RT and suggesting possible changes to the inhibitor which might
enhance its binding still further. The extensive structure/activity
relationship study reported by Pauwels [251 is pertinent to this, in
particular, if we consider inhibitory concentration values for TIBO
derivatives related by a single change to the CI-TIBO we have
studied (R8291 3). Thus, for changes to the phenyl ring: R82913
(9-CI), 33 nM; R82150 (H), 44 nM; R85255 (9-CI, 10-CI), 25 nM;
R86183 (8-CI), 4.6 nM; R86775 (8-Br), 3.0 nM; R84674 (8-CH 3),
14 nM. Changes at the 6-position: R82913 [-CH2-CH=C(CH 3)2],
33 nM; R86162 I-CH 2-CH=C(CH 2CH3)2], 15 nM; R85787 (-CH 2-
cyclo-C4H7), 43 nM; R86777 [-CH 2-CH2-CH(CH3)2], 92 nM;
R86058 (-CH 2-CH2-cyclo-C 3H5), 334 nM.
bridging atoms between rings in the other NNIs [1,2,4].
This volume appears large enough to accommodate an
isopropyl group. TIBO derivatives have been synthesized
with substituents at the 8-position [25] and they are
indeed very potent inhibitors (up to 10 times more effec-
tive than 9-CI-TIBO (R82913) [25]; see legend to
Fig. 7). The potency of such inhibitors appears to increase
with the size of substituent, although none of the sub-
stituents for which data are available are very large.
Biological implications
Chemotherapy is at present the only weapon in
the very limited arsenal of treatments for AIDS.
Furthermore, all currently licensed drugs target
HIV reverse transcriptase (RT). While other tar-
gets, such as the protease of HIV, are being
actively investigated, there are compelling reasons
for wishing to understand how the presently avail-
able anti-AIDS compounds work and how viral
resistance to them is achieved. To date, the
inhibitors of RT appear to fall into two categories,
the nucleoside analogues that act via the active site
and cause chain termination (such as AZT and
the dideoxy nucleosides), and the so-called non-
nucleoside inhibitors (NNIs) that act indirectly by
binding to the enzyme near the active site both
creating and occupying a hydrophobic pocket, a
process which switches the enzyme into an inac-
tive conformation. We report the structure of
HIV-1 RT complexed with 9-chloro-TIBO
(Cl-TIBO; R82913) at 2.6 A resolution. The
inhibitor binds at the same site as other NNIs, but
is distorted from the conformation seen in crystals
of the pure compound [21], allowing Cl-TIBO to
mimic the binding of NNIs containing two hinged
rings. Inhibitor-protein interactions are predomi-
nantly hydrophobic and the protein conformation
corresponds to that seen in complexes with other
tight-binding NNIs [4].
The CI-TIBO structure, taken together with other
studies, allows us to propose how the NNIs
achieve their binding affinity and specificity (the
selectivity of the NNIs for HIV-l-infected cells in
tissue culture can be far greater than the selectiv-
ity of the nucleoside analogues). Although this
specificity is a desirable pharmacological property,
it is also the Achilles heel of the compounds
because the protein side chains that form the
binding site are potentially very variable. As a
result of this, within a matter of days in the clinic
[26], virus populations highly resistant to the
compounds are selected from the extremely popu-
lous virus quasi-species (pool of variant viruses) in
an infected individual. Resistance occurs by a
common mechanism involving the repeated use of
a small subset of mutations. The complete conser-
vation of certain residues, such as Trp229 and
Leu234 strongly suggests that, although these
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compounds invite facile escape mechanisms, there
are limits to the changes that can be accommo-
dated without incurring a significant attenuation
in the viral phenotype. Although we do not yet
fully understand these constraints, the database of
structures for complexes of HIV-1 RT and NNIs
suggests that plasticity is restricted in certain
regions of the binding pocket. In addition, the
NNIs loosely mimic an internal protein surface
seen in the p51 subunit, and the requirement for
reasonable packing of the protein in that subunit
is likely to impose restrictions on successful muta-
tions. This may explain why mutations generally
function by eliminating stabilizing interactions,
rather than by blocking binding and it may be
useful to explicitly copy aspects of this interaction
in future compound design strategies.
Another indication that modes of resistance are
limited comes from the observation of 'cross-talk'
between different classes of RT inhibitors,
whereby mutations that confer resistance to cer-
tain NNIs, occurring in the background of resis-
tance to a nucleoside analogue, reconfer sensitivity
to that nucleoside analogue [27]. In summary,
although the development of resistance has led to
the failure of many initially promising anti-AIDS
therapies, we believe that strategies are now
emerging which might ameliorate the problem.
The failure of modelling exercises to fully predict
the mode of association of Cl-TIBO with HIV-1
RT alerts us to the limitations of current method-
ologies. The intensive study of cases such as this,
which are problematic because of the combina-
tion of extensive hydrophobic interactions and
protein-drug flexibility, should help develop
approaches with greater predictive power. In this
paper, with simple tools such as the analysis of
common volumes, we begin such an endeavour
for HIV-1 RT.
Materials and methods
Crystallographic data collection
The crystallization of RT-NNI complexes has been described
previously [11]. Orthorhombic crystals (space group P212121)
of the RT/C1-TIBO complex were grown at 40C by macro-
scopic seeding using sitting drops equilibrated against reservoirs
of 6% polyethylene glycol (PEG) 3400 with a standard MacI1-
vane pH 5.0 citrate-phosphate buffer (48.5 mM citric acid,
103 mM Na2HPO4). These crystals were then subjected to
partial dehydration by slow equilibration against 46% PEG
3400. This equilibration increased the order in the crystals
(enabling higher resolution data to be collected) as well as pro-
viding cryoprotection allowing the crystals to be flash-cooled.
Diffraction data were collected on Station 9.6 at the SRS,
Daresbury Laboratory, UK (March 1995) by the oscillation
method. Data frames of 1.50 oscillations were recorded using a
30 cm diameter MAR Research imaging plate placed 375 mm
away from the crystal with exposures measured by dose
(typically 150 s). The crystal was flash-cooled to 105 K in a
stream of nitrogen gas from a Cryostream (Oxford Cryo-
systems, Oxford, UK), which allowed 63 data images to be
collected from a single crystal with negligible radiation damage.
Autoindexing and data reduction were performed with
DENZO [28], the resulting data set being 81% complete for
reflections from 25-2.6 A resolution (Table 1). The crystal had
unit cell dimensions a=138.8 A, b=115.8 A and c=66.2 A,
which represents the smallest cell volume we have yet observed
for these orthorhombic crystals. Comparison with our other
RT crystal forms [5,11] suggests that this crystal form
(designated F) results from further shrinkage of crystal form D
on cooling. Further data, comprising a partial data set, were
collected from a single crystal flash-cooled to 100 K on BL4 at
the European Synchrotron Radiation Facility (ESRF),
Grenoble, France (February 1995). The crystal was grown as a
complex of RT with HEPT, partial dehydration by slow
equilibration against PEG 3400 also removed the inhibitor [5].
9-Cl-TIBO (at a concentration of 0.5 mM) was then soaked
into this crystal over a period of 36 h prior to data collection.
Images were recorded on a 30 cm MAR Research imaging
plate placed 270 mm away from the crystal and using radiation
of wavelength 0.995 A. Diffraction was observed to 2.8 A
resolution, although the crystal was poorly ordered in one
direction showing diffraction to little better than 4 A. The unit
cell dimensions were a=136.6 A, b=109.2 A, c=70.8 A (crystal
form E). Images were processed using DENZO [28] to
produce a partial data set of 11667 unique reflections with an
Rmerge of 6.6% (see Table 1). This represents a data set which is
44% complete for reflections from 30-2.8 A resolution.
Structure determination and refinement
The principal data set (crystal form F) was phased using the
model for the RT-nevirapine complex in the most closely
related cell (form D [4], excluding water and inhibitor mol-
ecules). This model was refined against the Cl-TIBO data, ini-
tially using data from 15-6.0 A, treating the model as a single
rigid body (R-factor=0.408); then as two rigid groups (p66 and
p51 subunits, R-factor=0.404); and, finally by treating the nine
domains as rigid groups and refining against data from
15-4.0 A resolution (R-factor=0.323). All refinements were
performed using X-PLOR [29) with the Engh and Huber
force-field parameters [30]. An Fobs I - I Fcalc I difference map
phased from this model clearly showed the bound Cl-TIBO
molecule at the NNI site and slight conformational changes to
nearby residues. The map allowed the inhibitor to be posi-
tioned and oriented unambiguously. The protein model was
rebuilt based on a 2 1 Fobs I - Fcalc I electron-density map using
the program FRODO [31] on an Evans and Sutherland ESV
workstation. The resulting model was then subjected to simu-
lated annealing [32] and restrained individual temperature fac-
tor refinement. Due to the low ratio between the number of
reflections and the number of parameters to be refined, atoms
distant from the NNI-binding site (defined as atoms more than
25 A from the Ca of Tyr188) were tightly restrained to their
position in the nine-domain rigid-body refined model and
strong stereochemical restraints were employed. Further
rounds of such restrained refinement (with a bulk solvent cor-
rection as implemented in X-PLOR [29]) and model rebuild-
ing resulted in the current model. This model has an R-factor
of 0.224 for all data from 25-2.6 A resolution and stereochem-
istry typified by rms deviations from ideality of 0.007 A and
1.4° for bond lengths and angles, respectively (Table 1). Only
those water molecules for which well-defined density and fea-
sible hydrogen-bonding possibilities existed were modelled
into the structure.
926 Structure 1995, Vol 3 No 9
The ESRF-derived partial data set was phased initially by nine-
domain rigid-body refinement of a form E model against these
data. The resulting maps confirmed both the presence of
C1-TIBO and a domain arrangement similar to that observed
in the form E unliganded RT model (data not shown). Rigid-
body refinement of individual domains of the form F
RT/C1-TIBO structure against the ESRF CI-TIBO data set
was performed and this provided a model which could be
directly compared with the unliganded RT (Fig. 5).
Anisotropic scaling in X-PLOR reduced the R-factor after
rigid-body refinement from 0.410 to 0.375.
Visualization methods
Figures 4a-d, 5 and 7 were produced using a version of
MOLSCRIPT version 1.4 [33] with modifications by RE and
rendered with Raster3D [34]. Figures 2 and 3a,c were pro-
duced using the program 'O' version 5.10 [35]. Figure 6a-c
were created using SybylTM version 6.1 (Tripos, Inc., St. Louis,
MO). These figures were displayed on a Silicon Graphics
workstation using IRIS® ShowcaseTM (Silicon Graphics, Inc.,
Mountain View, CA) for annotation. Figures 1 and 3b were
produced using CSC ChemDrawTM (Cambridge Scientific
Computing, Inc., Cambridge, MA).
Atomic coordinates for the RT/Cl-TIBO complex have been
deposited with the Brookhaven Protein Data Bank, for release
one year from the date of publication.
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